Lineage Cell Therapeutics Statistics
Total Valuation
LCTX has a market cap or net worth of $301.65 million. The enterprise value is $250.66 million.
| Market Cap | 301.65M |
| Enterprise Value | 250.66M |
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LCTX has 249.30 million shares outstanding. The number of shares has increased by 11.32% in one year.
| Current Share Class | 249.30M |
| Shares Outstanding | 249.30M |
| Shares Change (YoY) | +11.32% |
| Shares Change (QoQ) | +10.12% |
| Owned by Insiders (%) | 5.00% |
| Owned by Institutions (%) | 26.90% |
| Float | 187.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.41 |
| Forward PS | 16.95 |
| PB Ratio | 5.60 |
| P/TBV Ratio | 26.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.89, with a Debt / Equity ratio of 0.05.
| Current Ratio | 6.89 |
| Quick Ratio | 6.72 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.22% and return on invested capital (ROIC) is -21.18%.
| Return on Equity (ROE) | -98.22% |
| Return on Assets (ROA) | -12.92% |
| Return on Invested Capital (ROIC) | -21.18% |
| Return on Capital Employed (ROCE) | -22.55% |
| Weighted Average Cost of Capital (WACC) | 12.48% |
| Revenue Per Employee | $191,935 |
| Profits Per Employee | -$833,844 |
| Employee Count | 77 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.28M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.96% in the last 52 weeks. The beta is 1.51, so LCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | +40.96% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 1.60 |
| Relative Strength Index (RSI) | 41.47 |
| Average Volume (20 Days) | 1,086,589 |
Short Selling Information
The latest short interest is 26.08 million, so 10.46% of the outstanding shares have been sold short.
| Short Interest | 26.08M |
| Short Previous Month | 25.58M |
| Short % of Shares Out | 10.46% |
| Short % of Float | 13.93% |
| Short Ratio (days to cover) | 18.80 |
Income Statement
In the last 12 months, LCTX had revenue of $14.78 million and -$64.21 million in losses. Loss per share was -$0.28.
| Revenue | 14.78M |
| Gross Profit | -4.18M |
| Operating Income | -22.87M |
| Pretax Income | -69.29M |
| Net Income | -64.21M |
| EBITDA | -22.14M |
| EBIT | -22.87M |
| Loss Per Share | -$0.28 |
Balance Sheet
The company has $53.38 million in cash and $2.39 million in debt, with a net cash position of $50.99 million or $0.20 per share.
| Cash & Cash Equivalents | 53.38M |
| Total Debt | 2.39M |
| Net Cash | 50.99M |
| Net Cash Per Share | $0.20 |
| Equity (Book Value) | 52.70M |
| Book Value Per Share | 0.22 |
| Working Capital | 48.02M |
Cash Flow
In the last 12 months, operating cash flow was -$22.11 million and capital expenditures -$480,000, giving a free cash flow of -$22.59 million.
| Operating Cash Flow | -22.11M |
| Capital Expenditures | -480,000 |
| Depreciation & Amortization | 723,000 |
| Net Borrowing | -59,000 |
| Free Cash Flow | -22.59M |
| FCF Per Share | -$0.09 |
Margins
| Gross Margin | -28.28% |
| Operating Margin | -154.73% |
| Pretax Margin | -468.86% |
| Profit Margin | n/a |
| EBITDA Margin | -149.83% |
| EBIT Margin | -154.73% |
| FCF Margin | n/a |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.32% |
| Shareholder Yield | -11.32% |
| Earnings Yield | -21.28% |
| FCF Yield | -7.49% |
Analyst Forecast
The average price target for LCTX is $5.50, which is 354.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.50 |
| Price Target Difference | 354.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 60.01% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
LCTX has an Altman Z-Score of -2.82 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.82 |
| Piotroski F-Score | 4 |